University of Washington

University of California

Optikira LLC

Dustin James Maly

Bradley J Backes

Feroz R Papa

Kayode K Ojo

Wesley C Van Voorhis

Eric T Larson

Wilhelmus G J Hol

Ethan Merritt

Scott A Oakes

Gayani Perera

Likun Wang

Richard McCulloch Keenan

Erkang Fan

Stephen R Plymate

Ben Whittaker

George Hynd

Jonathan Mark Sutton

Charles Reynolds

Jamie Knight

Rama Subba Rao Vidadala

Wilhelmus Gj Hol

Jon Sutton

Wilhelmus GJ Hol

Disclosed herein are, inter alia, compounds modulating Inositol-Requiring Enzyme 1α (IRE1α) and IRE1β activity and methods of use thereof for treating IRE1α-mediated and IRE1β-mediated disorders.

Substituted pyrimidines as IRE1 kinase inhibitors

Disclosed herein, inter alia, are compounds for inhibiting IRE1α and uses thereof.

IRE1α inhibitors and uses thereof

Disclosed herein, inter alia, are substituted quinazolin-2-amines and isoquinolin-3-amines for inhibiting IRE1&#x3b1; and uses thereof.

IRE1&#x3b1; inhibitors and uses thereof

Provided herein, inter alia, are substituted imidazo[1,5-&#x3b1;]pyrazine compounds, compositions and methods for treating or preventing an IRE1&#x3b1;-related disease or disorder. In certain embodiments, the disease or disorder is selected from the group consisting of a neurodegenerative disease, a demyelinating disease, cancer, an eye disease, a fibrotic disease, and diabetes. 

Substituted imidazo[1,5-a]pyrazines for IRE1 inhibition

Described herein, inter alia, are certain substituted imidazo[1,5-a]pyrazines of formula (I) and methods of using the same for modulating the activity of Ire1. 

Substituted imidazo[1,5-a]pyrazines for modulation of IRE1

Compositions and methods for the treatment of toxoplasmosis, caused by the infectious eukaryotic parasite() and for the treatment of cryptosporidiosis, caused by the infectious eukaryotic parasites() and() are described. In particular, the present disclosure is directed to compositions and methods for inhibiting eithercalcium dependent protein kinases (TgCDPKs) orandcalcium dependent protein kinases (CpCDPKs) using pyrazolopyrimidine and/or imidazo[1,5-a]pyrazine inhibitors, of the formula, 

Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases

Described herein, inter alia, are certain substituted imidazolopyrazines of formula (I) and methods of using the same for modulating the activity of Ire1. 

Substituted imidazolopyrazine compounds and methods of using same

The present disclosure is directed to compositions and methods for inhibiting either() calcium dependent protein kinases (TgCDPKs) or() and() calcium dependent protein kinases (CpCDPKs) using pyrazolopyrimidine and/or imidazo[1,5-a]pyrazine inhibitors, of the Formula (I), wherein the variables X, Y, Z, R, and Rare defined herein.

Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases

Compositions and methods for the treatment of toxoplasmosis, caused by the infectious eukaryotic parasite() and for the treatment of cryptosporidiosis, caused by the infectious eukaryotic parasites() and() are described. In particular, the present disclosure is directed to compositions and methods for inhibiting eithercalcium dependent protein kinases (TgCDPKs) orandcalcium dependent protein kinases (CpCDPKs) using pyrazolopyrimidine and/or imidazo[1,5-a]pyrazine inhibitors, of the formula, wherein the variables X, Y, Z, L, R, and Rare defined herein.

The present disclosure is generally directed to bumped kinase inhibitor (BKI) compositions and methods for treating cancer.

Bumped kinase inhibitor compositions and methods for treating cancer

The present disclosure is directed to compositions and methods for inhibiting either() calcium dependent protein kinases (TgCDPKs) or() and() calcium dependent protein kinases (CpCDPKs) using pyrazolopyrimidine and/or imidazo[1,5-&#x3b1;]pyrazine inhibitors, of the Formula (I), wherein the variables X, Y, Z, R, and Rare defined herein.

Described herein, inter alia, are compositions and methods of using the same for modulating the activity of Ire1 using for example, substituted imidazopyrazine compounds.

Growing community of inventors

Seattle, WA, United States of America

Dustin James Maly